Observational data does more harm than good
News in brief …
Cost containment policies - can the industry survive?
News in brief …
Look beyond price - consider all costs associated with depression
Cost considerations …
World Bank report focuses on health
NHS ‘mission’ to base decisions on evidence
Alglucerase - a ‘paradigm’ of innovative drug therapy?
Ondansetron prophylaxis - costs outweigh benefits
Cost considerations …
News from the European Symposium on Pharmacoeconomics : Gent, Belgium May 1994
Benzodiazepine usage falling in the US
Cost education effective for optimising parenteral drug use
SSRI prescribing unwarranted for suicide prevention
Cost-effective strategies for managing acid-related diseases
No cost savings with epoetin for premature neonates
Quality of Life Aspects
A need for specific measures
Moclobemide favoured over fluoxetine for depression?
How to conduct a ‘careful’ cost analysis for migraine
Your Questions Answered
Glossary of Terms Used
A bold step for Eli Lilly
News in brief …
Rapid growth in UK health insurance